Drug intelligence / Profile preview

[11C]NOP-1A

Development stage: Phase 1
Lead developer: National Institute of Mental Health
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[11C]NOP-1A is a PET radioligand developed for imaging nociceptin/orphanin FQ peptide (NOP) receptors in the brain. It has high affinity (Ki, 0.15 nM) and appropriate lipophilicity (measured logD, 3.4) for PET brain imaging. The radioligand shows high brain uptake, specific binding, and can be quantified using compartmental modeling. It has a short half-life of 11C (20.4 min), which allows a subject to participate in multiple scans in one day.

Other names: (S)-3-(2'-fluoro-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]-1-yl)-2-(2-fluorobenzyl)-N-methylpropanamide

Targets

NOP (Nociceptin/orphanin FQ peptide receptor)

Beyond the preview

Go deeper on [11C]NOP-1A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]NOP-1A.

Explore the full profile